Navigation Links
Neptune Technologies decided not to re-price options
Date:9/12/2008

LAVAL, QC, Sept. 12 /PRNewswire-FirstCall/ - The Board of Directors of Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB) decided not to re-price any options including the previously announced 850,000 options owned by officers and directors.

About Neptune Technologies

Neptune researches and develops proprietary bioactive ingredients and products for nutraceutical and pharmaceutical applications and is sponsoring clinical research to demonstrate the therapeutic benefits in various medical indications. The Company patents its intellectual property, protects its industrial secrets and innovations and continuously expands its intellectual property portfolio. Neptune has already obtained many regulatory approvals allowing commercialization of its products in various geographic markets and has filed for and is expecting additional approvals. Neptune continues to strongly support its strategic development plan to form partnerships with worldwide leaders in the nutraceutical industries. Neptune has signed agreements with Nestle and Yoplait, worldwide leading food manufacturers, and paved its entrance into the global functional food market.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the

adequacy or accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.


'/>"/>
SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
2. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
3. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
4. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
5. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
6. Neptune Technologies expands into medicinal markets in Asia Pacific
7. Neptune Technologies receives GRAS notification in the United States
8. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
9. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
10. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
11. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CALABASAS, Calif. , Jan. 19, 2017 /PRNewswire/ ... Mathias Schmidt , Ph.D., as chief executive ... board of directors. Dr. Schmidt brings to ArmaGen more ... on the research and development of biotherapeutics and ... biopharmaceutical executive with the diverse experience and skillset ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical ... spectrum of drug and device development, and Prism Clinical Research , a ... today announced Verified Clinical Trials (VCT) has been selected by both ...
(Date:1/18/2017)... ... January 18, 2017 , ... Opal ... using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, combining ... a compact business-card sized form factor suitable for prototyping, testing, and production-ready integration. ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm Slone Partners ... commitment to the advancement of the clinical trials segment. Hosted in Miami, this ... trial planning and management. , As executive talent specialists in the industries ...
Breaking Biology Technology:
(Date:12/20/2016)... 2016 The rising popularity of mobility ... is stoking significant interest in keyless access systems. ... low energy (BLE), biometrics and near-field communication (NFC) ... of wireless technologies in the automotive industry. This ... access systems opens the market to specialist companies ...
(Date:12/16/2016)... 2016 Research and Markets has announced the ... Forecast to 2021" report to their offering. ... The biometric vehicle access system ... CAGR of 14.06% from 2016 to 2021. The market is estimated ... reach 854.8 Million by 2021. The growth of the biometric vehicle ...
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):